EMA Wellness Bolsters Executive Leadership to Scale its Market Leading Clinical Trial Platform

New CMO, EVP Operations and SVP Clinical Solutions bring track records of scalable growth and innovation for sponsors, sites and CROs implementing successful clinical trials

BOSTON, Oct. 8, 2025 /PRNewswire/ -- EMA Wellness (EMAW) the market leader in providing a unified eCOA, analytics and adjudication platform to sponsor and CRO partners announces the appointments of Dr. Andrew Cutler, MD as Chief Medical Officer, Dr. Miranda Mann, PhD as Executive Vice President of Operations and Dr. Patrick Harrington, PhD as Senior Vice President of Clinical Solutions. Dr Cutler's clinical research track record and experience as a thought leader working with sponsors to design and implement trials in neuro psychiatry will expand EMAW's thought leadership in driving patient and site centric engagement. Dr Mann's experience as a GM at Syneos Health, and COO at Evolution Research Group and Elligo Health Research will facilitate EMAW's ability to scale data, clinical and delivery for sponsors and sites. Dr Harrington's experience creating and growing Syneos Health's clinical surveillance team will continue to grow EMAW's efforts to enhance patient and ratings quality.

"The timing to add industry professionals with strong performance track records to EMAW leadership is perfect," said EMAW CEO Colin Bower. "We will continue to focus on adding value to existing partners while scaling the platform to allow new sponsors to reap the benefits of using a singular code base and AI to efficiently and effectively collect, analyze and quality assure multimodal data, including primary ratings, in their clinical trials."

Dr. Cutler founded Florida Clinical Research Center in 1998, grew it into a multi-site company, and sold it to Meridien Research, creating the largest multidisciplinary clinical trial site network in Florida. Dr. Cutler has worked with sponsors and CROs in the successful approval of more than 25 drugs. Dr. Cutler's experience across a wide array of trial designs and conditions provides thought leadership for sponsors in the design and implementation of their trials, including how to best recruit and engage patients, and facilitate the generation of the highest quality ratings.

"I'm proud to leverage my expertise and over 30 years of research experience by joining such a high quality organization with truly outstanding technology and people, many of whom I've known, worked with and admired for many years," said Dr. Cutler. "I believe that EMA Wellness has become the industry standard and through our platform and services can maximize the quality of clinical trials and the chance of success for clinical trials."

"I've worked with Andy for over 15 years, and he is universally known and respected in our industry for a reason," said Bower. "His knowledge and experience are vast, but people also thoroughly enjoy collaborating with him, and that is an important combination of traits that will add to the clinical and collegial ethos of EMAW."

Dr. Mann earned her Ph.D. in clinical neuropsychology and brings deep scientific, clinical, and operational expertise to her role. Her experience in leadership roles across site organizations and CROs provides valuable insight into multiple perspectives within the clinical trial ecosystem. Her work at Syneos Health - launching and growing its presence in Japan to 500+ employees and leading the strategic expansion across the Asia Pacific region - is directly relevant to EMA Wellness as it continues to scale its global presence. Dr. Mann will be responsible for all clinical, data, and delivery operations at EMA Wellness, reporting directly to the CEO. "EMA Wellness has built an exceptional foundation that unites technology, data, and clinical expertise to advance the quality and efficiency of clinical trials," said Dr. Mann. "I am proud to join this talented team as we scale our operations and continue advancing the standards of data integrity, patient experience, and customer focus for sites, sponsors, and CROs."

"I'm delighted to have Miranda join our team," said Bower. "She has already integrated our delivery and clinical teams and incorporated scalable data migration and analytics in a way that will materially improve our utility to sponsor partners across all of these areas, thereby having a real and positive impact on the quality of the clinical trials in which we are involved."

"In addition to Drs. Cutler and Mann, Dr Harrington's experience starting and scaling the Syneos Health's clinical surveillance team provides important depth and breadth to our clinical team" said Bower. "The fact that Andy, Miranda and Pat have all worked together will substantially reduce the time it takes to have a materially positive impact on EMAW and our partners."

This leadership expansion comes on the heels of EMAW's continued global ascension as the new market standard in eCOA, digital data collection and integration and clinical analysis in CNS clinical trials. EMAW's web-based technology and singular code base drive the feature functionality of its proprietary GIANT™ platform. GIANT™ unifies multimodal data collection, analytics, ratings adjudication, data access and transfer in fully auditable white box environment. EMAW has further driven new standards of data quality by utilizing AI for ratings surveillance, effectively using LLMs to independently score and qualitatively review recorded clinical interviews. This functionality allows sponsors to quality assure 100% of ratings faster and at less cost than traditional rater surveillance methodologies. EMAW's blinded clinical outcome analytics also takes place within the platform ensuring full audit trails, and EMAW uniquely provides sponsors real time access to their data via API or regular data transfers. EMAW has developed its technology organically and internally, not by acquisition of competing or disparate technologies.

About EMAW

EMA Wellness (EMAW) was founded in 2018 by clinical research leaders, technology experts, and industry executives to improve outcomes in CNS clinical trials through contemporary, validated technology. The EMAW platform integrates eCOA, analytics, and adjudication within a unified web-based environment built on a single code base. It enables sponsors and CROs to collect, visualize, and analyze multimodal clinical data in real time, including ecological momentary assessments and other real-world data, to support data quality, patient safety, and operational efficiency. Today, the EMAW platform is used in more than 25 countries and by over 250 sites.

EMAW applies innovative AI-based methods and validated models to complement expert clinician review, accelerating signal detection and supporting meaningful human interpretation and decision-making within a fully auditable environment. The platform also provides rights-based data access, automated audit trails, and direct data transfer via API, ensuring transparency and traceability across studies.

The EMAW platform is a resource multiplier for sponsor partners who are better able to collect more data, receive faster insights, integrate clinical adjudication and remediation workstreams, improve subject selection, monitor site and rater performance, detect AESI's, address protocol deviations and modifications and medical adherence.

EMAW is fundamentally differentiated from traditional eCOA and related technologies because it was built using a single code to create a web-based technology platform which can be used from any laptop, tablet or phone with a standard browser to collect active or passive data, in the clinic or the real world. Sites, PI's, raters, reviewers and other trial stakeholders with requisite rights can access data instantly and adjudicate or remediate within the platform in real time. The platform is also highly scalable and therefore extremely cost effective for our sponsor partners.

No other trial technology offers a comparable, integrated combination of speed, configurability and adjudication functionality in a singular platform.

Contact: Colin Bower, CEO, [email protected]

SOURCE EMA Wellness